Licensing status

Publication and contact information

Ophthalmic disease


IL-12; IL-27

In vitro and mouse studies suggest a heterodimeric cytokine could help treat uveitis. In mouse T cell proliferation and differentiation assays, a recombinant engineered cytokine composed of the a-subunit of mouse Il-27 and the b-subunit of mouse Il-12 decreased proliferation and differentiation of T helper type 1 (Th1) and T helper type 17 (Th17) cell compared with vehicle. In a mouse model of uveitis, the engineered cytokine decreased disease markers including inflammation and increased anti-inflammatory regulatory T cell levels compared with no treatment. Next steps could include testing the engineered cytokine in mouse models of other inflammatory diseases.

SciBX 5(37); doi:10.1038/scibx.2012.986
Published online Sept. 20, 2012

Patent and licensing status unavailable

Wang, R.-X. et al. J. Biol. Chem.; published online Aug. 30, 2012;
Contact: Charles E. Egwuagu,
National Institutes of Health,
Bethesda, Md.